The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting.
 
Neil J. Shah
Honoraria - MedNet, LLC; MedNet, LLC; MJH Life Sciences
Consulting or Advisory Role - Exelixis; Graticule; Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis
Travel, Accommodations, Expenses - Merck
 
Rituparna Bhattacharya
Employment - Merck; Otsuka (I)
Stock and Other Ownership Interests - Merck
 
Ning Ning
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Bayer (Inst); BeiGene (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Merck (Inst); Otsuka (Inst); Takeda (Inst)
 
Reshma Shinde
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jordana Schmier
No Relationships to Disclose
 
Malinda Tan
No Relationships to Disclose
 
Traci LeMasters
No Relationships to Disclose
 
Murali Sundaram
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Aveo; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Merck; Pfizer; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb